AHCPR Plans Health Care Market, Managed Care Research Centers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 8
Volume 8
Issue 8

ROCKVILLE, Md-The Agency for Health Care Policy Research (AHCPR) plans to spend up to $11 million to fund two or three research centers to conduct studies of the health care market and managed care. The aim is to help policy makers understand, monitor, and anticipate how changes in the nation’s market-driven health care system affect costs, access to services, and quality of care. Interested researchers have until Sept. 2 , 1999, to submit letters of intent.

ROCKVILLE, Md—The Agency for Health Care Policy Research (AHCPR) plans to spend up to $11 million to fund two or three research centers to conduct studies of the health care market and managed care. The aim is to help policy makers understand, monitor, and anticipate how changes in the nation’s market-driven health care system affect costs, access to services, and quality of care. Interested researchers have until Sept. 2 , 1999, to submit letters of intent.

Related Videos
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
Related Content